Immediate Impact
30 standout
Citing Papers
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Development of NK cell-based cancer immunotherapies through receptor engineering
2024 Standout
Works of Anne Yeakey being referenced
DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma
2021
DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Anne Yeakey | 26 | 35 | 179 | 167 | 56 | 18 | 307 | |
| Takehiro Hasegawa | 29 | 54 | 76 | 107 | 26 | 23 | 352 | |
| G Foulon | 23 | 66 | 102 | 150 | 32 | 18 | 284 | |
| Sonia de Arriba | 19 | 36 | 67 | 43 | 21 | 22 | 333 | |
| Christian Ascoli | 40 | 36 | 151 | 126 | 11 | 27 | 300 | |
| Philippe Van Wilder | 20 | 36 | 25 | 50 | 14 | 21 | 318 | |
| Threnesan Naidoo | 78 | 53 | 30 | 36 | 21 | 15 | 256 | |
| Natasha Slhessarenko | 5 | 26 | 138 | 26 | 11 | 17 | 334 | |
| Hui Yang | 16 | 70 | 34 | 53 | 69 | 28 | 304 | |
| Silvia De Pietri | 22 | 74 | 46 | 46 | 23 | 19 | 294 | |
| Calvino Cheng | 6 | 43 | 42 | 20 | 60 | 17 | 281 |
All Works
Login with ORCID to disown or claim papers
Loading papers...